HYCOR Biomedical Raises $20M to Expand Allergy Testing

HYCOR Biomedical Raises $20M to Expand Allergy Testing

HYCOR Biomedical can test whether people are allergic to everything from bees to nuts. But the Garden Grove-based diagnostic company is expanding their research and development capacity into less common areas.

Every year, 200,000 Americans land in the hospital due to allergies. And the Asthma and Allergy Foundation of America reports more than 50 million Americans suffer from allergies annually.

Last month, the company, led by president and chief executive Dr. Fei Li, closed a Series B round. Li declined to disclose the investors, but said the nearly four-decade-old company is attempting to catapult itself past leaders in the allergy diagnostic field such as Massachusetts-based Thermo Fisher.

"They have about 70% of the marketshare worldwide. But their product is really dated — it launched in the early 1980s," said Li. She believes HYCOR's NOVEOS system, which was approved by the FDA in 2019, will put it ahead of competitors.

The NOVEOS instrument, which looks like a large, inconspicuous gray box, is loaded with patient blood samples by doctors and runs allergy tests on the samples. The process is entirely automated, so doctors can tend to other matters while waiting for results.

Li said small biotech companies for years have been at a disadvantage to large companies like Thermo Fisher because the allergen field is so labor intensive. The sheer number of allergens that need to be researched and tested often can't be handled by smaller labs. But, she said, the NOVEOS requires less blood, enabling more samples to be analyzed quicker. It's also a big plus when testing pediatric patients.

"Allergy is a little bit different. People are allergic to so many different things," said Li. "The entry barrier is really high. So over all these years, not only was the company developing a new platform, but at the same time the company is developing hundreds of assays on the platform."

Each individual assay tests an allergy to a different substance, and according to Li, HYCOR had to redevelop over 800 different assays.

HYCOR was founded in 1982, with a focus in developing diagnostic tools to detect allergies and autoimmune diseases. While its legacy product, the HYTEC 288 Allergy Platform, was profitable, the company decided to redesign its product in 2011, to keep pace with emerging technologies. At the same time, Thermo Fisher acquired a leading allergy diagnostic company, Phadia, for about $3.5 billion, and became the dominant in the allergy diagnostics field.

In the past year, HYCOR has pivoted its distribution focus slightly to help combat the pandemic. The company assisted with distribution of COVID-19 PCR testing kits made by NaGene Diagnosis.

Subscribe to our newsletter to catch every headline.

I wasn't a believer until I saw him in action. At a Tom Ferry event at the Seattle Convention Center, I observed thousands of people worshipping Tom Ferry, then and now, a legendary real estate coach, as he doled out words of wisdom during his presentations.

In many ways, Tom learned from the best. His dad is Mike Ferry, also a legendary real estate coach. Tom started working in sales at his dad's company, the Mike Ferry Organization, at 19. He eventually earned the position of president.

Read more Show less
Spencer Rascoff

Spencer Rascoff serves as executive chairman of dot.LA. He is an entrepreneur and company leader who co-founded Zillow, Hotwire, dot.LA, Pacaso and Supernova, and who served as Zillow's CEO for a decade. Through his startup studio and venture capital firm, 75 & Sunny, Spencer is an active angel investor in over 75 companies and is incubating several more.

Despite — or in many cases because of — the raging pandemic, 2020 was a great year for many tech startups. It turned out to be an ideal time to be in the video game business, developing a streaming ecommerce platform for Gen Z, or helping restaurants with their online ordering.

But which companies in Southern California had the best year? That is highly subjective of course. But in an attempt to highlight who's hot, we asked dozens of the region's top VCs to weigh in.

We wanted to know what companies they wish they would have invested in if they could go back and do it all over again.

Read more Show less
Ben Bergman

Ben Bergman is the newsroom's senior finance reporter. Previously he was a senior business reporter and host at KPCC, a senior producer at Gimlet Media, a producer at NPR's Morning Edition, and produced two investigative documentaries for KCET. He has been a frequent on-air contributor to business coverage on NPR and Marketplace and has written for The New York Times and Columbia Journalism Review. Ben was a 2017-2018 Knight-Bagehot Fellow in Economic and Business Journalism at Columbia Business School. In his free time, he enjoys skiing, playing poker, and cheering on The Seattle Seahawks.